Enliven Therapeutics Inc [ELVN] stock prices are up 8.28% to $21.58 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ELVN shares have gain 9.82% over the last week, with a monthly amount glided 4.05%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Enliven Therapeutics Inc [NASDAQ: ELVN] stock has seen the most recent analyst activity on June 16, 2025, when Goldman initiated its Buy rating and assigned the stock a price target of $37. Previously, BTIG Research started tracking the stock with Buy rating on December 13, 2024, and set its price target to $42. On September 09, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $37 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $32 on June 11, 2024. Mizuho initiated its recommendation with a Buy and recommended $34 as its price target on April 09, 2024. Jefferies started tracking with a Buy rating for this stock on March 29, 2023, and assigned it a price target of $27.
The stock price of Enliven Therapeutics Inc [ELVN] has been fluctuating between $13.30 and $30.03 over the past year. Currently, Wall Street analysts expect the stock to reach $45.5 within the next 12 months. Enliven Therapeutics Inc [NASDAQ: ELVN] shares were valued at $21.58 at the most recent close of the market. An investor can expect a potential return of 110.84% based on the average ELVN price forecast.
Analyzing the ELVN fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.32 and Total Capital is -0.38.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 20.23 points at the first support level, and at 18.88 for the second support level. However, for the 1st resistance point, the stock is sitting at 22.53, and for the 2nd resistance point, it is at 23.49.
Ratios To Look Out For
It’s worth pointing out that Enliven Therapeutics Inc [NASDAQ:ELVN]’s Current Ratio is 21.06. In addition, the Quick Ratio stands at 21.06 and the Cash Ratio stands at 7.28.
Transactions by insiders
Recent insider trading involved Patel Anish, CHIEF OPERATING OFFICER, that happened on Jul 07 ’25 when 6667.0 shares were sold. Officer, Patel Anish completed a deal on Jul 07 ’25 to buy 6667.0 shares. Meanwhile, CHIEF FINANCIAL OFFICER Hohl Benjamin sold 3250.0 shares on Jun 27 ’25.
